The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

Illumina (ILMN) has returned to profitability, reporting high quality earnings and trading at $123.54 per share, which is below its estimated fair value of $166.88. The company is forecasting EPS ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Illumina’s third quarter results reflected stable year-over-year revenue and a notable beat on Wall Street’s profit ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit ...

Ultima Genomics, a developer of an innovative, ultra-high throughput sequencing architecture, today announced that Jason Kang, an industry veteran has joined as the Company's commercial leader in the ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...

Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass ...